Inclusion Criteria:

- Participants must be male and have a pathological diagnosis of prostate cancer

- Pathological diagnosis of prostate cancer must be confirmed and on file with CRA
prior to study entry.

- No treatment (surgery, radiation, or hormones) prior to study entry.

- PSA between 2.0 and 10.0 ng/ml.

- If PSA is >10.0, patient must have been on Active Surveillance for 12 months prior to
study initiation.

- No known allergy to soy or soy products.

- The patient is not currently taking more than 2 grams of genistein a day in
nutritional or diet enhancing supplements (OTC supplements).

- Participant has not been on any previous GCP clinical trial.

- Normal Chemistry values prior to study entry.

Exclusion Criteria:

- No pathological documentation of prostate cancer.

- Prior treatment for prostate cancer.

- PSA >10.0 ng/ml but not on Active Surveillance for 12 months.

- Allergy to soy or soy products.

- Abnormal chemistry values.